E-mail  |   Log in
News Center
Ningbo Aucheer Biotechnology Co., Ltd
audir
audir
audir
Academic Conference|Aucheer PlGF creates a new era of preeclampsia management

Academic Conference|Aucheer PlGF creates a new era of preeclampsia management

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2019-08-30
  • Views:0

(Summary description)Hypertension in pregnancy and preeclampsia are currently one of the main causes of death in pregnant women. Preeclampsia causes 15% of premature births worldwide, and related complications cause 42% of the deaths of pregnant women worldwide, and affect more than 8.5 million pregnant women worldwide. Pregnant women cause medical expenses as high as 120 billion U.S. dollars and have long-term adverse effects on their offspring.

Academic Conference|Aucheer PlGF creates a new era of preeclampsia management

(Summary description)Hypertension in pregnancy and preeclampsia are currently one of the main causes of death in pregnant women. Preeclampsia causes 15% of premature births worldwide, and related complications cause 42% of the deaths of pregnant women worldwide, and affect more than 8.5 million pregnant women worldwide. Pregnant women cause medical expenses as high as 120 billion U.S. dollars and have long-term adverse effects on their offspring.

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2019-08-30
  • Views:0
 
 

Click "Aocheng Bio" above to follow and get the latest information!

 

Hypertension during pregnancy and preeclampsia are currently one of the main causes of death in pregnant women,Caused by preeclampsia15% of preterm births worldwide,Related complications42% of pregnant women die globally,At the same time affectedmore than 8.5 million pregnant women worldwide,Caused medical expenses up to 120 billion U.S. dollars,and it has long-term adverse effects on the offspring.

 

In order to increase the importance of hypertension in pregnancy and preeclampsia, explore the prediction and prevention of diseases,Ningbo Aocheng Biotechnology Co., Ltd. invited experts from the province to gather in Ningbo with colleagues in obstetrics and gynecology to hold the "Pre-eclampsia Screening and Prevention Management Seminar" on August 18, 2019.

 

 

Director Zhang Hongping, deputy chairman of the Wenzhou Perinatal Branch, emphasized at the meeting that delayed diagnosis and treatment is the main cause of passive treatment. Therefore, the prediction and prevention of preeclampsia has attracted more and more clinical attention.

 

 

 

 

 

 
 

 

Director of the Department of Obstetrics, Ningbo Women's and Children's Hospital Chen An'er focused on the analysis of the International Federation of Obstetrics and Gynecology (FIGO) "Practical Guidelines for the Screening and Prevention of Preeclampsia in Early Pregnancy".The guidelines were formulated by a team of experts from 17 countries. The guidelines systematically analyzed the status of preeclampsia, which is one of the main causes of death in pregnant women, and can cause short-term and long-term fetal complications.andOld age, first birth, past history, obesity, family history, and related complications are all high-risk factors for preeclampsia.

 

However, the current early screening methods mainly identify risk factors from the demographic characteristics and medical history of pregnant women. Such methods have low detection rates, high false positive rates, and defects, and are not effective tools for predicting preeclampsia. Therefore, the guidelines recommend the use of Bayesian models to combine maternal characteristics and prior risk of medical history with the results of various biophysical and biochemical tests.Predict preeclampsia in the first trimester,at the same time,for people at high risk who are screened, take aspirin every night from 11-14+6 weeks to 36 weeks gestation to prevent the occurrence of preeclampsia.

 

 

 

Director He Jing is the director of the Obstetrics Department of the Obstetrics Hospital of Zhejiang University School of Medicine, the deputy head of the obstetrics group of the Obstetrics and Gynecology Branch of the Chinese Medical Association, and the former and appointed chairman of the Perinatal Branch of the Zhejiang Branch of the Chinese Medical Association.At the meeting,Based on years of experience and related cases, Director He Jing affirmed the importance of early prediction and prevention of preeclampsia from a clinical perspective, and proposed that PlGF in the first trimester can be used for preeclampsia screening and the significance of aspirin for preeclampsia prevention.

 

Liu Binjie, Medical Director of Ningbo Aocheng Biotechnology Co., Ltd., introduced "Aucheer PlGF to Create a New Era of Preeclampsia Management" at the meeting.Through the mechanism of preeclampsia, it is found that its onset is closely related to placental function, which is mainly induced by the remodeling of the uterine spiral arterioles caused by the decrease of placental growth factor.And from the perspective of evidence-based medicine, how to use PlGF to manage this pregnancy disease, which is more common than Down’s syndrome,that is, the comprehensive assessment of PlGF and other factors in the first trimester, the detection of PlGF in the second trimester to strengthen the detection risk reassessment, and the auxiliary diagnosis of preeclampsia in the third trimester.

 

 

Ningbo Aocheng focuses on providing reliable, fast and convenient in vitro diagnostic reagents for clinics from early detection, diagnosis, prevention to detection of diseases.Committed to providing professional maternal and child health clinical diagnosis solutions,With the Aucheer PlGF test reagent, it will usher in a new era of preeclampsia risk assessment and management.

相关资讯

Aucheer
Contact:86-574-87732259
Technical Support:400-008-6588
Aucheer
Business Mailbox:info1@aucheer.net
HR Mailbox :hr@aucheer.net
Aucheer
Address: No. 885, Chunhua Road, Haishu District, Ningbo City, Zhejiang Province
North 4th Floor, Science and Technology Building, Ningbo Haichuang Park
Aucheer
Auchen Bio
Aucheer
Auchen Medical

© 2021 Ningbo Aucheer Biotechnology Co., Ltd | 浙ICP备17032133号-2Powered by www.300.cn